Singapore markets close in 1 hour 4 minutes
Explore/

The Fight Against COVID19

The Fight Against COVID19

19.94k followers14 symbols Watchlist by TREA

Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.

Curated by TREA

TREA analyzes over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: FDA (Food and Drug Administration), NIH (National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2 among others.

Performance

WatchlistChange today1-month return1-year returnTotal return
The Fight Against COVID19+2.14%---
^GSPC-0.47%+0.99%+23.33%+3998.01%

14 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
JNJJohnson & Johnson158.46-4.30-2.64%4:00 pm GMT-514.42M8.18M416.54B
ABBVAbbVie Inc.107.74+0.41+0.38%4:02 pm GMT-59.25M7.22M190.26B
PFEPfizer Inc.33.49-0.33-0.98%4:02 pm GMT-541.46M41.92M186.15B
SNYSanofi45.89+0.09+0.20%4:00 pm GMT-53.13M2.75M115.12B
GSKGlaxoSmithKline plc33.61-0.77-2.24%4:00 pm GMT-57.64M5.52M83.91B
GILDGilead Sciences, Inc.61.4-1.39-2.21%4:00 pm GMT-510.40M9.01M76.97B
MRNAModerna, Inc.154.81+6.43+4.33%4:00 pm GMT-513.45M21.63M61.26B
TAKTakeda Pharmaceutical Company Limited16.71-0.04-0.24%4:00 pm GMT-54.78M3.62M53.07B
REGNRegeneron Pharmaceuticals, Inc.450.57-2.62-0.58%4:00 pm GMT-51.19M1.04M48.27B
BNTXBioNTech SE109.03-3.30-2.94%4:00 pm GMT-51.01M3.12M26.25B
NVAXNovavax, Inc.231.23+9.73+4.39%4:00 pm GMT-52.03M4.69M15.55B
VIRVir Biotechnology, Inc.62.63-1.48-2.31%4:00 pm GMT-5952.88k1.60M7.98B
INOInovio Pharmaceuticals, Inc.11.1-0.39-3.39%4:00 pm GMT-512.26M15.69M2.27B
  • AstraZeneca Divests Entire 7.7% Stake In Moderna For $1B: The Times
    Benzinga

    AstraZeneca Divests Entire 7.7% Stake In Moderna For $1B: The Times

    British-based drugmaker AstraZeneca plc (NASDAQ: AZN) has sold its 7.7% stake in Moderna Inc. (NASDAQ: MRNA) for more than $1 billion, the Times reported Sunday. What Happened: AstraZeneca disposed of its stake in Moderna following the U.S. biotechnology company’s coronavirus vaccine breakthrough, according to the Times report. It isn't clear over what period AstraZeneca sold its holding, the report added. The news of the stake sale comes just as Johnson & Johnson’s (NYSE: JNJ) single-shot coronavirus vaccine candidate received approval as the third vaccine for emergency use in the U.S. Moderna’s coronavirus vaccine was approved by U.S. regulators in December last year for emergency use against COVID-19. While reporting its fourth-quarter financial results in late February, Moderna said it expects product sales of $18.4 billion from the vaccine this year. Why It Matters: AstraZeneca’s 7.7% stake made it the second-largest investor in Moderna last year. The company could use the cash from the stake sale to develop its own drugs and complete its $39 billion acquisition of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). AstraZeneca, which developed its COVID-19 vaccine in partnership with Oxford University, sells the vaccine on a non-commercial basis, unlike Moderna’s vaccine. The company’s vaccine has not yet received approval in the U.S. As per the Times report, AstraZeneca will continue its partnership with Moderna on other disease treatments and may sell its COVID-19 vaccine on a commercial basis in the future if the virus becomes endemic. Price Movement: AstraZeneca’s shares closed more than 1% lower at $48.38 on Friday, while Moderna’s shares closed 4.3% higher at $154.81. Photo by Marco Verch on Flickr See more from BenzingaClick here for options trades from BenzingaPfizer, Moderna, J&J Pledge To Make 240M COVID-19 Vaccine Doses Available In US By March-EndModerna Prepares To Increase Doses In Each COVID-19 Vaccine Vial To Counter Production Woes© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Reuters

    UPDATE 1-U.S. eyes Tuesday deliveries of J&J vaccine; urges minorities to get shots

    Initial deliveries of the newly approved Johnson & Johnson COVID-19 vaccine should start on Tuesday, senior Biden administration officials said on Sunday, saying they hoped to boost lagging vaccination rates among minorities. The officials acknowledged that vaccination rates among Black and brown Americans were "not where we ultimately want them to be", but said measures had been put in place to boost those numbers, and sought to assure minorities that the vaccines were safe. Federal officials were also closely monitoring distribution to ensure it was equitable, they said.

  • AstraZeneca has sold its stake in Moderna for more than $1 billion -The Times
    Reuters

    AstraZeneca has sold its stake in Moderna for more than $1 billion -The Times

    The report added that it was not clear over what period British-based AstraZeneca sold its holding in Moderna. AstraZeneca and Moderna did not immediately respond to requests for comment. AstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University COVID-19 vaccine on a commercial basis in future if the virus becomes endemic, the report added.